References
- De Jong E. M., Seegers B. A., Gulnick M. D., Boezeman J. B., van de Kerkhof P. C. Psoriasis of the nail associated with disability in a large number of patients: Results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300–3
- De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357–62
- Nandedkar‐Thomas M. A., Scher R. K. An update on disorders of the nails. J Am Acad Dermatol 2005; 52: 877–87
- Bianchi L., Bergamin A., de Felice C., Capriotti E., Chimenti S. Remission and time resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52: 736–7
- Rich P., Scher R. K. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206–12
- Cassetty C. T., Alexis A. F., Shupack J. L., Strober B. E. Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol 2005; 52: 1101–2
- Ormerod A. D., Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004; 150: 630–2
- Altmeyer P. J., Matthes U., Pawlak F., Hoffmann K., Frosch P. J., Ruppert P., et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double‐blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977–81
- Kolbach D. N., Nieboer C. Fumaric acid therapy in psoriasis: Results and side‐effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769–71
- Mrowietz U., Christophers E., Altmeyer P. Treatment of psoriasis with fumaric acid esters: Results of a prospective multicenter study. Br J Dermatol 1998; 138: 456–60
- Balasubramaniam P., Stevenson O., Berth‐Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150: 741–6